The Normal Bone Marrow and Management of Toxin-Induced Stem Cell Failure

Chemical Warfare Agents: Toxicology and Treatment, Second Edition

Volumn , Issue , 2007, Pages 443-466

  Treleaven, Jennifer G ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bone marrow embryological development; Bone marrow harvesting; Macrophage Colony stimulating factor (M CSF); Normal bone marrow and stem cell failure management; Recombinant human stem cell factor (rHuSCF)

Indexed keywords

EID: 34648877986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470060032.ch22     Document Type: Chapter

References (77)

1. Albeda SM and Buck CA (1990). Integrins and other cell adhesion molecules. FASEB J, 4, 2868-2880.
2. Aoun E, Shamseddine A, Chehal A et al. (2003). Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center. Transfusion, 43, 1672-1676.
3. Antonchuk J, Sauvageau Gand Humphries RK (2002). HoxB4-induced expansion of adult hematopoietic cells ex vivo. Cell, 109, 39-45.
4. Ayash LJ, Elias A, HuntMet al. (1994). Recombinant human erythropoietin for the treatment of anaemia associated with autologous bone marrowtransplantation. Br J Haematol, 87, 153-161.
5. Bence-Bruckler I, Bredeson C, Atkins H et al. (1998). A randomised trial of granulocyte-colony stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant, 22, 965-969.
6. Bernstein ID, Andrews RG and Zsebo KM (1991). Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lincells, and the generation of colony-forming cell progeny from DC34+lin-cells cultured with Interleukin3, granulocyte-colony stimulating-factor, or granulocyte-macrophage colony stimulating factor. Blood, 77, 2316-2321.
7. Biggs JC, Atkinson KA, Booker V et al. (1995). Prospective randomised double-blind trial of the invivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical donors. The Australian bone marrow Transplant Study Group. Bone Marrow Transplant, 15, 129-134.
8. Bishop NJ,Williams DM, Compston JC et al. (1995). Osteoporosis in severe congenital neutropenia treated with granulocyte colony stimulating factor. Br J Haematol, 89, 927-928.
9. Bodey GP, BuckleyM, Sathe YS et al. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Int Med, 64, 328-340.
10. Boeckh M, Berrey MM, Bowden RA et al. (2001). Phase I evaluation of the RSV-specific humanised monoclonal antibody palivizumab in hematopoietic stem cell transplant recipients. J Infect Dis, 184, 350-354.
11. Bortin MM and Buckner CD (1983). Major complications of marrow harvesting for transplantation. Exp Hematol, 11, 916-921.
12. Bradley TR and Metcalfe D (1966). The growth of mouse bone marrow cells in vitro. Aus J Exp Biol Med Sci, 44, 287-300.
13. Broudy VC (1997). Stem cell factor and haematopoiesis. Blood, 90, 1345-1364.
14. Carnot P and Deflandre C (1906). Sur l'activite haemopoietique du serum au cours de la regeneration du sang. Compt rend Acad Sci (Paris), 143, 384-386.
15. Chao NJ, Schriber JR, Long GD et al. (1994). A randomised study of erythropoietin and granulocytecolony stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood, 83, 2823-2828.
16. Co-operative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukaemia (1988). Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukaemia. N Eng J Med, 6, 902-907.
17. Dale DC, Guerry D IV, Wewerka JR et al. (1979). Chronic neurtopenia. Medicine, 58, 128-144.
18. Demirer T, Ayli M, Dagli M et al. (2002). Influence of post-transplant recombinant human granulocyte colony stimulating factor administration on pertransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol, 118, 1104-1111.
19. Dignani MC and Anaissie EJ. (2002). Candida. In: Clinical Mycology, Volume 1, 1st Edition (EJ Anaissie, M McGinnis and MA Pfaller, eds), pp. 195-239. Philadelphia, USA: Churchill Livingstone.
20. EORTC International Antimicrobial Therapy Cooperative Group. (1987). Ceftazidime combined with short and long course amikacin for empirical therapy of gram-negative bacteraemia in cancer patients with granulocytopenia. New Eng J Med, 317, 1692-1698.
21. Flaharty KK, Grimm AM and Vlasses PH (1989). Epoetin: human recombinant erythropoietin. Clin Pharm, 8, 769-782.
22. Gloor W (1930). Ein Fall von geheilter Myeloblastenleukaemie. Münch Med Wochen, 77, 1096-1098.
23. Goldberg SL, Mangan KF, Klumpp TR et al. (1995). Complications of peripheral blood stem cell harvesting: review of 554 PBSC. J Hematother, 4, 85-90.
24. Goodman JL,Winston DJ, GreenfieldRAet al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Eng J Med, 326, 845-851.
25. Hasegawa M, Matsuki Y, Ozawa S et al. (1968). The role of erythropoietin in aplastic anemia-some aspects of the etiology and treatment of asplastic anemia. Keio J Med, 17, 109-123.
26. Hillyer CD, Lankford KV, Roback JD et al. (1999). Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6,7 and 8. Transfus Med Rev, 13, 1-17.
27. Hughes WT, Armstrong D, Bodey GP et al. (1990). From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis, 161, 381-396.
28. Jacobs K, Shoemaker C, Rudersdorf R et al. (1985). Isolation and charactertisation of genomic and cDNA clones of human erythropoietin. Nature, 313, 806-810.
29. Jin NR, Hill RS, Petersen FB et al. (1985). Marrow harvesting for autologous marrow transplantation. Exp Hematol, 13, 879-884.
30. Jones RN (1999). Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis, 29, 495-502.
31. Junghanss C, Leithauser M, Wilhelm S et al. (2001). High-dose etoposide phosphate and G-CSF mobilises peripheral blood stem cells in patients that previously failed to mobilise. Ann Hematol, 80, 96-102.
32. Klaesson S, Ringden O, Ljungman P et al. (1994). Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant, 13, 397-402.
33. Levine AS, Siegel SE, SchreiberADet al. (1973). Protected environments and prophylactic antibiotics-a prospective controlled study of their utility in the therapy of acute leukaemia. New Engl J Med, 288, 477-483.
34. Link H, Boogaerts MA, Fauser AA et al. (1994). A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood, 84, 3327-3335.
35. Love LJ, Schimpff SC, Schiffer CA et al. (1980). Improved prognosis of granulocytopenic patients with gram-negative bacteraemia. Am J Med, 68, 643-648.
36. MacVittie TJ, Farese A, Herodin F et al. (1996). Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthetic SC-55494 and recombinant human granulocyte-colony stimulating factor. Blood, 97, 4129-4135.
37. Magagnoli M, Sarina B, Balzarotti M et al. (2001). Mobilising potential of ifosphamide/vinorelabinebased chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant, 10, 923-927.
38. Mannick JA, Lochte HL, Ashley CA et al. (1960). Autografts of bone marrow in dogs after lethal total body irradiation. Blood, 15, 255-266.
39. Mathá G, Jammet H, Pendic B et al. (1959). Transfusions and grafts of homologous bone marrow in humans accidentally irradiated to high doses. Rev Fr Etudes Clin Biol, 4, 226-238.
40. Mathá G, Schwarzenberg L, Amiel JL et al. (1965). Bone marrow Transplantation in the treatment of leukaemia. Presse Med, 10, 1043-1046.
41. Mayer P, Schnntze E, Lam C et al. (1991). Recombinant murine granulocyte macrophage colony stimulating factor augments recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis, 163, 584-590.
42. Metcalf D. (1991). Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Nat Acad Sci USA, 88, 1310-1314.
43. Metcalf D and Moore MA (1971). Haemopoietic cells. In: Frontiers in Biology, Volume 24 (Neuberger A & Tatum EL, eds), pp. 172-271. Amsterdam, The Netherlands: North-Holland.
44. Miyake T, Chung CK and Goldwasser E (1977). Purification of human erythropoietin. J Biol Chem, 252, 5558-5564.
45. Moore MA and Metcalf D (1970). Ontogeny of the haemopoietic system; yolk origin of in-vivo and invitro colony forming cells of the developing mouse embryo. Br J Haematol, 18, 279-296.
46. Nash RA, Schuening FG, SeidelKet al. (1994). Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hemopoietic recovery after otherwise lethal total body irradiation. Blood, 83, 1963-1970.
47. Neelis KJ, Hartong SC, Egeland T et al. (1997). The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage colony-stimulating factor or granulocyte colony-stimulating factor in myelosuppressed Rhesus monkeys. Blood, 90, 2565-2573.
48. Nemunaitis J, Rabinowe SN, Singer JW et al. (1991). Recombinant granulocyte-macrophage colonystimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Eng J Med, 324, 1773-1778.
49. Osgood EE, Riddle MC and Matthews TJ (1939). Aplastic anaemia treated with daily transfusions and intravenous marrow; case report, Ann Int Med, 13, 357-367.
50. Ozer H, Armitage JO, Bennett CL et al. (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Onc, 18, 3558-3585.
51. Pamphilon D, Rider J, Barbara J et al. (1999). Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion Med, 9, 115-123.
52. Pearson MM, Rogers PD, Cleary JD et al. (2003). Voriconazole: a new triazole antifungal agent. Ann Pharm, 37, 420-432.
53. Porteous DD and Lajtha LG (1966). On stem cell recovery after irradiation. Br J Haematol, 12, 177-188.
54. Price TH, Bowden RA, BoeckhMet al. (2000). Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infection in hemopoietic stem cell transplantation. Blood, 95, 3302-3309.
55. Ravankar SG and Graybill JR (2002). Antifungal therapy. In: Clinical Mycology, Volume 1 1st Edition (EJ Anaissie, M McGinnis and MA Pfaller, eds), pp. 157-196. Philadelphia, USA: Churchill Livingstone.
56. Samonis G, Ralston K, Karl C et al. (1990). Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis, 12, S369-S373.
57. Schiffer CA (1996). Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood, 88, 3675-3685.
58. Schimpff SC, Saterlee W, Young VM et al. (1971). Empirical therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New Eng J Med, 284, 1061-1065.
59. Schofield R (1978). The relationship between the spleen colony-forming cell and the haemopoietic stem cell. A hypothesis. Blood Cells, 4, 7-25.
60. Schroeder ML (2002). Transfusion-associated graftversus-host disease. Br J Haematol, 117, 275-287.
61. Schuening FG, Storb R, Goehle S et al. (1989). Effect of recombinant human granulocyte colonystimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood, 74, 1308-1313.
62. Schuening FG, Appelbaum FR, Deeg HJ et al. (1993). Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood, 81, 20-26.
63. Strauss RG (1995). Clinical perspectives of granulocyte transfusion: efficacy to date. J Clin Apheresis, 10, 114-118.
64. Takahashi T, Wada T, Mori M et al. (1996). Over expression of the granulocyte colony stimulating factor gene leads to osteoporosis in mice. Lab Invest 74, 827-834.
65. Tavassoli M (1991). Embryonic and fetal hemopoiesis: an overview. Blood Cells, 17, 269-281.
66. Till JE and McCulloch EA (1961). A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Rad Res, 14, 213-222.
67. Till JE and McCulloch EA (1980). Hemopoietic stem cell differentiation. Biochim Biophys Acta, 605, 431-459.
68. Van de Berg BC, Malghem J, Lecouvet FE et al. (1998). Magnetic resonance imaging of normal bone marrow. Eur Radiol, 8, 1327-1334.
69. Vannucchi AM, Bosi A, Ieri A et al. (1996). Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for haematological malignancies: a randomised trail. Bone Marrow Transplant, 17, 527-531.
70. Visser JWM, Bauman JGJ, Mulder AH et al. (1984). Isolation of murine pluripotetic hemopoietic stem cells. J Exp Med, 50, 1576-1590.
71. Vogler JB III and Murphy WA (1988). Bone marrow imaging. Radiology, 168, 679-693.
72. Vose JM and Armitage JO (1995). Clinical applications of hematopoietic growth factors. J Clin Onc, 13, 1023-1035.
73. Wakerly L, Craig A-M, Malek M et al. (1996). Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimisation analysis. J Hosp Infect, 33, 35-48.
74. Wingard JR, Merz WG, Rinaldi MG et al. (1991). Increase in Candida krusei among patients with bone marrow transplantation and neutropenia treated with fluconazole. NewEng J Med, 325, 1274-1277.
75. Wingard JR, Merz WG, Rinaldi MG et al. (1993). Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother, 37, 1847-1849.
76. Winston DJ, Maziarz RT, Chandrasekar PH et al. (2003). Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. A multicenter randomized trial. Ann Int Med, 138, 705-713.
77. Worton RG, McCulloch EA and Till JE (1975). Physical separation of haemopoietic stem cells differing in their capacity for self-renewal. J Exp Med, 130, 91-102.